February 19, 2021
Authored and Edited by Melissa C Santos, Ph.D.; Esther H. Lim; Christina Ji-Hye Yang; Elizabeth D. Ferrill
In Mojave Desert Holdings, LLC, v Crocs, Inc., No. 2020-1167 (Fed. Cir. Feb. 11, 2021), the Federal Circuit held that a successor-in-interest is a real party-in-interest to an inter partes reexamination.
Crocs sued U.S.A. Dawgs for infringement of U.S. Patent No. D517,789. U.S.A. Dawgs filed a third-party request for inter partes reexamination of the ’789 patent. U.S.A. Dawgs then filed for bankruptcy and sold its assets to Dawgs Holdings, LLC, including all “assets, properties and rights of every kind and nature.” Dawgs Holdings then assigned all rights to Mojave. The Board ultimately upheld the patent and denied Mojave’s petition to change the real party-in-interest. Mojave appealed.
The Federal Circuit held that because all rights had been assigned, including its interest in the inter partes reexamination, Mojave was the successor-in-interest. Accordingly, the Court held that the Board erred in denying Mojave’s petition to substitute for U.S.A. Dawgs as the real party-in-interest and that Mojave had standing to challenge to the ’789 patent. The Federal Circuit also held that U.S.A. Dawg retained the ability to file a protective notice of appeal, and doing so sufficed to confer jurisdiction on the Court. The Court then granted Mojave’s motion to substitute on appeal.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.